TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05224128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 200mg
Description: Imatinib have to be taken 200mg/day orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
Study: NCT05674864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus
Description: Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus
Description: Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
Study: NCT05660525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.
Study: NCT04394572

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: All patients included in the study will have blood sample
Study: NCT05660525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine Replacement Therapy Patch
Description: All participants will receive at least 4 weeks of the NRT Patch.
Study: NCT05399407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health e-coaching
Description: Management of overweight / obesity
Study: NCT06626087

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Prototype artificial intelligence algorithm
Description: Developed by the University of Hong Kong

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: LI-RADS
Description: The Liver Imaging Reporting and Data System (LIRADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
Study: NCT05506982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Given PO

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: supportive care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04336579

Intervention type: BEHAVIORAL
Intervention: Diaphragmatic Breathing
Description: Simple diaphragmatic breathing exercise
Study: NCT06154122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Upper Limb Rehabilitation Games
Description: A VR upper limb rehabilitation programme prescribed by the therapist with games chosen depending on the exercise task required and the level of difficulty adapted to the ability of the individual. The participant will use the VR system's user interface to navigate through menus to set their gameplay preferences and select which games to play.~The games of the intervention will involve facilitating and replicating upper limb movements including gross movements of the shoulder, such as rotation, abduction and addiction, movements of the upper and lower arms, such as flexion and extension of the elbow, and hand, wrist and finger movements, including wrist pronation supination, and finger flexion and extension, as well as tenodesis movements, grasping, and pinching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper Limb Rehabilitation
Description: Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Limb Rehabilitation
Description: Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
Study: NCT06143683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: On post-operative day (POD) 1, active range of motion exercises of the elbow joint will be initiated under the observation and guidance of the physical therapy team. On POD 3, the patient will be transitioned to active as well as active-assisted range of motion exercises. The physical therapy team will provide an exercise sheet handout to patients (Appendix 5) and encourage patients to do the exercise for 10 repetitions, 2 times a day, holding each stretch for 30 seconds. On POD3, patients with non-meshed sheet hand grafts will undergo active range of motion exercises of the hands under the observation and guidance of the physical therapy team. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Mobilization
Description: Following surgery, the patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint. From POD 1 to 4, the patient's affected extremity will be kept elevated and immobilized with a flexion blocking splint. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions. The physical therapy team will guide the patient on POD5 through range of motion exercises, starting with active, then active assisted, then passive as tolerated.
Study: NCT05537246

Intervention type: PROCEDURE
Intervention: PWV
Description: All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.

Intervention type: PROCEDURE
Intervention: PWV
Description: All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.
Study: NCT05534282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)
Description: Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy with Children (MUT-K) (exp. group)
Description: Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)
Description: Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
Study: NCT06272916

Intervention type: DRUG
Intervention: Aminophylline , magnesium sulphate and placebo
Description: Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
Study: NCT04064697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
Study: NCT06578299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab and Paclitaxel ± Pertuzumab
Description: Inetetamab and Paclitaxel ± Pertuzumab Inetetamab：was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Paclitaxel：Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously on the first day of every three weeks, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Pertuzumab：was administered as an intravenous (IV) loading dose of 840mg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420mg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
Study: NCT05981586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric strengthening exercises
Description: Comparative effects 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric strengthening exercises
Description: Comparative effects 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric strengthening exercises
Description: Comparative effects 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotonic strengthening exercises
Description: Comparative effects 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotonic strengthening exercises
Description: Comparative effects 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotonic strengthening exercises
Description: Comparative effects 2
Study: NCT05345041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep it Movin'
Description: Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go 4 Life Self Guided Education
Description: Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
Study: NCT06470841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG Combined With Venetoclax and Azacytidine
Description: Patients were treated by CHG Combined With Venetoclax and Azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14.
Study: NCT05557487

Intervention type: DIAGNOSTIC_TEST
Intervention: Low dose computed tomography
Description: 1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low dose computed tomography
Description: 1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test.
Study: NCT04876027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 RAs
Description: GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calorie restricted diet
Description: Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: calorie restricted diet
Description: Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
Study: NCT05378867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRS003
Description: * TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: China-approved Bevacizumab
Description: • Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: China-approved Bevacizumab
Description: • Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus.
Study: NCT05173467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Invasion-controlled Surgery
Description: The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional-open Surgery
Description: This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
Study: NCT05557487

Intervention type: DIAGNOSTIC_TEST
Intervention: Low dose computed tomography
Description: 1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test.
Study: NCT06567457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Description: intramuscular injection
Study: NCT05937750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
Description: Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
Study: NCT06105008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disitamab Vedotin
Description: 2.0 mg/kg intravenous (lV) infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: 2.0 mg/kg intravenous (lV) infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg intravenous (lV) infusion every 2 weeks
Study: NCT06506916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimekizumab
Description: Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimekizumab
Description: Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.
Study: NCT05828498

Intervention type: DIETARY_SUPPLEMENT
Intervention: THE Mediterranean diet
Description: The Mediterranean diet was applied to the patients with bacterial vaginitis selected randomly. diet content and application techniques were explained to the patient.
Study: NCT01333592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAD-1229
Study: NCT06147193

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: with baseline intervention and power training interventions
Description: Group A (with power training ) was treated with~* squats jump,~* change of direction speed,~* countermovement jump,~* bench press,~* Romanian deadlift~* barbell squats,~* resistance band sprints,~* stair sprints~* weighted sled pulls

Intervention type: OTHER
Group type: OTHER
Intervention: baseline interventions and without power training interventions
Description: Group B (without power training) was treated with~* squats jump~* change of direction speed~* countermovement jump~* barbell squats~* resistance band sprints~* stair sprints~* Weighted sled pulls.